Funding Clinical Trials

Funding Clinical Trials

Our Agency funds clinical trials testing promising stem cell-based treatments for currently incurable diseases or disorders to help patients with unmet medical needs. For basic information about stem cell trials, visit our Clinical Trials 101 page. For a list of clinical trials that are a result of early-stage CIRM grants click here.

CIRM Clinical Dashboard

Disease Areassort ascending Investigator Organization Phase Trial Status Targeted Enrollment Detail
  • X-linked Chronic Granulomatous Disease
 Donald Kohn University of California, Los Angeles Phase 1/2 Active, not recruiting 10
Douglas Losordo Caladrius Biosciences Phase 2 Completed 113
Howard Foyt ViaCyte, Inc. Phase 1/2 Active, not recruiting 69
Howard Foyt ViaCyte, Inc. Phase 1/2 Recruiting 75
Peter Stock University of California, San Francisco Phase 1/2 Recruiting 8
Bijan Nejadnik SanBio, Inc. Phase 2 Completed 163
Jane Lebkowski Geron Corporation Phase 1 Completed 5
Francois Binette Lineage Cell Therapeutics Inc. Phase 1/2 Completed 25
  • Spina Bifida
 Diana Farmer University of California, Davis Phase 1 Launching N/A
Dennis Slamon University of California, Los Angeles Phase 1 Recruiting 48
Pierre Caudrelier ExCellThera Inc. Phase 1 Launching N/A
David Williams Boston Children's Hospital Phase 2 Launching N/A
Joseph Rosenthal City of Hope, Beckman Research Institute Phase 1 Recruiting 6
Donald Kohn University of California, Los Angeles Phase 1 Recruiting 6
Stephen Gottschalk St. Jude Children's Research Hospital Phase 1/2 Recruiting 28
Judith Shizuru Stanford University Phase 1/2 Recruiting 34
  • Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
 Morton Cowan University of California, San Francisco Phase 1 Recruiting 15
Donald Kohn University of California, Los Angeles Phase 2 Completed 10
  • Sarcoma
 Theodore Nowicki University of California, Los Angeles Phase 1 Recruiting 12
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
Henry Klassen jCyte, Inc Phase 2 Active, not recruiting 84
Henry Klassen University of California, Irvine Phase 1/2 Completed 28
Henry Klassen jCyte, Inc Phase 2 Active, not recruiting 84
  • Pulmonary Hypertension
 Michael Lewis Cedars-Sinai Medical Center Phase 1/2 Recruiting 26
Krystof Bankiewicz Brain Neurotherapy Bio Phase 1 Recruiting 12
Nancy Lane University of California, Davis Phase 1/2 Active, not recruiting 59
Kristen Johnson Calibr Phase 1 Completed 60
  • Multiple Myeloma
 Matthew Spear Poseida Therapeutics, Inc. Phase 1 Recruiting 220
Robert Dillman Caladrius Biosciences Phase 3 Closed 4
Antoni Ribas University of California, Los Angeles Phase 1 Recruiting 12
Steven Dubinett University of California, Los Angeles Phase 1 Recruiting 36
  • Leukocyte Adhesion Deficiency
 Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Recruiting 9
  • Leukemia, Acute Myeloid (AML)
 Colleen Delaney Nohla Therapeutics Inc Phase 2 Closed 146
  • Leukemia, Acute Myeloid (AML)
 Mark Chao Forty Seven Inc. Phase 1 Recruiting 287
Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 355
Samuel Strober Stanford University Phase 1 Active, not recruiting 15
Jeffrey Lawson Humacyte, Inc. Phase 3 Recruiting 240
Daniel Brennan Medeor Therapeutics, Inc. Phase 3 Recruiting 30
Everett Meyer Stanford University Phase 1 Recruiting 22
Stephanie Cherqui University of California, San Diego Phase 1/2 Recruiting 6
Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
Steven Deeks University of California, San Francisco Phase 1/2 Launching N/A
Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 13
John Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
Mehrdad Abedi University of California, Davis Phase 1/2 Recruiting 18
Rachel Smith Capricor, Inc Phase 2 Closed 156
Linda Marban Capricor, Inc Phase 2 Completed 25
  • COVID-19
 John Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
  • COVID-19
 Michael Matthay University of California, San Francisco Phase 2 Recruiting 120
  • COVID-19
 Xiaokui Zhang Celularity Inc Phase 1/2 Recruiting 86
  • Corneal Damage
 Sophie Deng University of California, Los Angeles Phase 1 Recruiting 20
Mark Chao Forty Seven Inc. Phase 1/2 Completed 78
Anthony Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 414
Christine Brown City of Hope, Beckman Research Institute Phase 1 Recruiting 92
Saul Priceman City of Hope, Beckman Research Institute Phase 1 Recruiting 39
Gayatri Rao Rocket Pharmaceuticals, Inc. Phase 1 Launching N/A
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Recruiting 9
Michael Pulsipher Children's Hospital of Los Angeles Phase 1/2 Recruiting 60
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Recruiting 24
Thomas Kipps University of California, San Diego Phase 1 Completed 26
Irving Weissman Stanford University Phase 1 Completed 88
  • Beta Thalassemia
 Bettina Cockroft Sangamo BioSciences, Inc. Phase 1/2 Active, not recruiting 6
Thomas Kipps University of California, San Diego Phase 1/2 Recruiting 156
Crystal Mackall Stanford University Phase 1 Recruiting 57
Ralph Kern BrainStorm Cell Therapeutics Phase 3 Active, not recruiting 261
Clive Svendsen Cedars-Sinai Medical Center Phase 1/2 Completed 18
  • Alpha Thalassemia Major
 Tippi MacKenzie University of California, San Francisco Phase 1 Recruiting 10
Mark Humayun University of Southern California Phase 1 Active, not recruiting 16
Icon for XLSX export